医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hoya Reports Third Quarter Results; Record Nine Months Results

2016年01月29日 PM07:45
このエントリーをはてなブックマークに追加


 

TOKYO

Hoya Corporation (TOKYO: 7741) today announced financial results for the third quarter ended December 31, 2015.

During the quarter, the Group sales totaled 127,645 million yen, decreasing by 0.4% from the same period last year. Pre-tax profit for the quarter was 31,179 million yen, while profit for the quarter was 24,034 million yen, which represented decrease of 14.0% and 17.5% respectively from last year when foreign exchange gain was reported due to the decline in the value of yen against U.S. dollar progressed.

In the Information Technology segment, demand of semiconductor and LCD panel-related products especially for smartphones and TVs was favorable and drove sales expansion. On the other hand, sales of glass disks for HDDs declined slightly because of encroachments into the PC market by smartphones and other devices. Overall sales in the Information Technology segment declined 3.2%.

In the Life Care segment, the contact lens retail business reported a major increase for the quarter, however sales of the eyeglass lenses business slightly decreased due to the negative impact of the foreign currency trends. In the medical related products, sales of intraocular lens business for the cataract surgery rose substantially because of recovery in the Japanese market and success in developing sales overseas markets, while sales of medical endoscopes weakened. As a consequence, overall sales in the Life Care segment were flat.

For the nine months ended December 31, 2015, HOYA posted record revenues of 384,048 million yen, record pre-tax profit of 95,938 million yen and record profit for the term of 74,824 million yen.

“Some weak businesses in the Information Technology segment seem to have hit the bottom, and we expect that growth in the Life Care segment will drive the Group performance in the coming year,” said Hiroshi Suzuki, chief executive officer of HOYA. “There is a great potential in the medical endoscope business and we will aggressively seek the opportunity for M&A.”

Hoya also announced the projected results for the fiscal year ending March 31, 2016. Hoya forecasts revenues of 505,000 million yen (up 3.1% compared to the previous year), pre-tax profit of 120,000 million yen (up 1.5%) and profit for the term of 93,500 million yen (up 0.6%).

 

Summary of Consolidated Financial Statement

(Millions of Yen: Rounded to the nearest million)
      Three months ended   Variance   Nine months ended   Variance
      Dec./14   Dec./15   (%) Dec./14   Dec./15   (%)
Revenue 128,206   127,645 -0.4 362,520   384,048 5.9
Profit before tax 36,240 31,179 -14.0 92,940 95,938 3.2
Profit for the term 29,142 24,034 -17.5 74,427 74,824 0.5
Basic earnings per share(yen)   68.25   58.14     173.47   178.56  

*Results are preliminary and unaudited.

 

The full reports are available at: www.hoya.com

About HOYA

Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company and the leading supplier of innovative high-tech and medical products. Hoya is active in the fields of healthcare and information technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, Hoya currently employs a multinational workforce of over 34,000 people. For more information, please visit http://www.hoya.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005349/en/

CONTACT

Hoya Group
Akiko Chiba, +81-3-3952-6416
Public Relation
HOYA-pr@hoya.com

同じカテゴリーの記事 

  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024